RxDoctor Payments Data

Yassin Ghanem, APRN

Psychiatric/Mental Health · Westlake, OHNPI 1689286726

Payments from drug & device makers

$9,070in general payments, 2019–2025

Across 637 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$956
  • Neos Therapeutics, LP$903
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$821
  • Lundbeck LLC$730
  • Axsome Therapeutics, Inc.$461
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$9,01699%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,070 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$28,085
Medicare patients
42
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl39$55,482
CaplytaLumateperone Tosylate15$28,151
TrintellixVortioxetine Hydrobromide20$10,260
Aripiprazole74$6,543
Atomoxetine Hcl19$2,085
Venlafaxine Hcl ErVenlafaxine Hcl61$1,618
Methylphenidate Er (La)Methylphenidate Hcl13$1,457
Duloxetine Hcl62$1,422
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl12$1,300
Paliperidone ErPaliperidone11$1,300
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,171
Bupropion XlBupropion Hcl59$1,086
Fluvoxamine Maleate15$1,034
Gabapentin96$950
Lamotrigine91$946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,424$55,48239 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$821$28,15115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$354$10,26020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Westlake

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →